Technical Analysis for IKNA - Ikena Oncology, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.58% |
| Alert | Time |
|---|---|
| Up 2% | about 23 hours ago |
| 60 Minute Opening Range Breakout | about 23 hours ago |
| Upper Bollinger Band Resistance | about 23 hours ago |
| Gap Down Partially Closed | about 24 hours ago |
| Gap Down Closed | about 24 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/07/2024
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Oncology Colorectal Cancer Signal Transduction Cancer Therapies Transcription Factors Novel Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Oncology Colorectal Cancer Signal Transduction Cancer Therapies Transcription Factors Novel Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.56 |
| 52 Week Low | 1.02 |
| Average Volume | 47,234 |
| 200-Day Moving Average | 1.56 |
| 50-Day Moving Average | 1.71 |
| 20-Day Moving Average | 1.71 |
| 10-Day Moving Average | 1.71 |
| Average True Range | 0.05 |
| RSI (14) | 54.34 |
| ADX | 29.46 |
| +DI | 27.79 |
| -DI | 8.38 |
| Chandelier Exit (Long, 3 ATRs) | 1.63 |
| Chandelier Exit (Short, 3 ATRs) | 1.81 |
| Upper Bollinger Bands | 1.73 |
| Lower Bollinger Band | 1.69 |
| Percent B (%b) | 0.75 |
| BandWidth | 2.70 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0006 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.85 | ||||
| Resistance 3 (R3) | 1.85 | 1.81 | 1.83 | ||
| Resistance 2 (R2) | 1.81 | 1.77 | 1.81 | 1.82 | |
| Resistance 1 (R1) | 1.76 | 1.75 | 1.79 | 1.76 | 1.81 |
| Pivot Point | 1.72 | 1.72 | 1.73 | 1.72 | 1.72 |
| Support 1 (S1) | 1.68 | 1.69 | 1.70 | 1.68 | 1.63 |
| Support 2 (S2) | 1.64 | 1.67 | 1.64 | 1.62 | |
| Support 3 (S3) | 1.59 | 1.64 | 1.61 | ||
| Support 4 (S4) | 1.59 |
